8,659 Shares in DexCom, Inc. $DXCM Acquired by USA Financial Formulas

USA Financial Formulas acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 8,659 shares of the medical device company’s stock, valued at approximately $747,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Plato Investment Management Ltd bought a new position in DexCom during the second quarter valued at approximately $782,000. Aurora Investment Counsel purchased a new stake in DexCom in the second quarter worth approximately $2,340,000. E Fund Management Co. Ltd. bought a new stake in DexCom in the 2nd quarter worth approximately $1,273,000. Silvant Capital Management LLC bought a new stake in DexCom in the 2nd quarter worth approximately $5,359,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in DexCom in the 2nd quarter worth approximately $89,940,000. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $86.04 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $32.47 billion, a PE ratio of 34.01, a price-to-earnings-growth ratio of 1.44 and a beta of 1.48. The firm’s 50 day moving average price is $87.61 and its 200-day moving average price is $75.86. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period in the previous year, the business posted $0.48 earnings per share. The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. Equities research analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 2,565 shares of the firm’s stock in a transaction on Monday, September 28th. The stock was sold at an average price of $86.15, for a total value of $220,974.75. Following the transaction, the executive vice president directly owned 123,478 shares of the company’s stock, valued at approximately $10,637,629.70. This trade represents a 2.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme M. Sylvain sold 3,638 shares of DexCom stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the transaction, the executive vice president owned 146,828 shares in the company, valued at $12,226,367.56. This trade represents a 2.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 49,313 shares of company stock worth $3,945,875. Insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus set a $95.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings raised DexCom from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, October 6th. BTIG Research raised their price target on DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Robert W. Baird set a $105.00 price target on DexCom in a research note on Friday, July 31st. Finally, Wells Fargo & Company lifted their price objective on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $92.43.

DexCom Company Profile

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.